Trial Profile
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/Ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Medroxyprogesterone (Primary)
- Indications HIV-1 infections; Pregnancy
- Focus Pharmacokinetics
- 20 Jun 2021 Results of a population pharmacokinetic analysis of data pooled from three ACTG studies (A5093, A5283 and A5338) published in the Clinical Pharmacology and Therapeutics
- 11 Mar 2020 Results (n=138) of pooled analysis from three clinical studies: ACTG A5093, ACTG A5283 and ACTG A5338 were presented at the 27th Conference on Retroviruses and Opportunistic Infections
- 24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.